During a Reagan-Udall Foundation meeting tied to the 30th anniversary of the US Food & Drug Administration’s Accelerated Approval pathway, earlier this month, agency officials came armed with data to help shape the narrative around the ongoing debate over potential reforms to the program.
The data help, in part, to counter the argument that there are countless products that gain approval using the accelerated...